COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement (BATTLE)
Sponsor: Conselho Nacional de Desenvolvimento Científico e Tecnológico
This PHASE4 trial investigates BCG and COVID-19 and is currently completed. Conselho Nacional de Desenvolvimento Científico e Tecnológico leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Dec 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE4
-
May 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Paulínia Municipal Hospital
- University of Campinas, Brazil
For direct contact, visit the study record on ClinicalTrials.gov .